Top Markets
Coin of the day
Curatis Holding AG Curatis Holding AG

Curatis Holding AG

CURN
Classificação em ações #20206
Curatis Holding AG specializes in the entire lifecycle of pharmaceutical... Curatis Holding AG specializes in the entire lifecycle of pharmaceutical products, including the procurement, advancement, and market release of medications specifically designed for the diagnosis, prevention, and management of rare and specialized medical conditions. The company's extensive product offerings span a broad array of therapeutic areas. These encompass treatments for antiplatelet conditions, metastatic hormone receptor-positive breast cancer, anti-arrhythmic disorders, nasal oil applications, Wilson's disease, antidotes for cyanide poisoning and digoxin toxicity, antihypotensive agents, therapies for bladder pain syndrome/interstitial cystitis, antibiotics, diagnostic tools for ophthalmology, antivirals, ophthalmic/antibiotic combinations, gentamycin collagen sponges, solutions for benign prostatic hyperplasia, immunomodulators, treatments for epilepsy and essential tremor, thyreostatics, therapies for hereditary tyrosinemia type 1, gastroenterological products, additional immunomodulators and thyreostatics, tranquilizers, Helicobacter pylori tests, phosphate binders, specialized nutritional support for dialysis patients, dermatological corticosteroids, antidotes for lead and mercury poisoning, corticostimulants, anti-fog agents, treatments for chorea associated with Huntington's disease, and antiepileptics. In addition to its commercialized portfolio, Curatis is actively engaged in developing new pharmaceutical compounds. Its pipeline includes C-PTBE-01, currently in Phase IIb clinical trials for treating peritumoral brain edema in pediatric patients; C-AM-01, undergoing Phase IIa trials for preventing severe migraine with aura; and C-MOH-01, also in Phase IIa for the treatment and prevention of medication overuse headache. Furthermore, KIN001 is in Phase I clinical trials, targeting rare inflammatory and fibrotic diseases. The company maintains its headquarters in Liestal, Switzerland.
Preço da ação
$25.88
Valor de mercado
$137.20M
Variação (1 dia)
2.05%
Variação (1 ano)
87.77%
País
CH
Negociar Curatis Holding AG (CURN)

Categoria

Histórico de preços das ações de Curatis Holding AG (CURN)
Preço de fecho mais alto: $25.29 em 2026-08-01

Preço de fecho mais baixo: $1.26M em 1999-04-01
Histórico de preços das ações da Curatis Holding AG de 1999 a 2026
Desempenho anual do preço das ações
Ano Desempenho
2026 (TTM) 54.44%
2025 2.02%
2024 524.76%
2023 -95.88%
2022 -83.81%
2021 -17.34%
2020 481.84%
2019 37.23%
2018 -52.65%
2017 -17.39%
2016 -30.62%
2015 -47.06%
2014 -44.60%
2013 13.03%
2012 8.19%
2011 -47.25%
2010 -0.13%
2009 146.64%
2008 -94.83%
2007 -25.49%
2006 -36.45%
2005 -14.30%
2004 -19.20%
2003 8.14%
2002 88.71%
2001 -91.53%
2000 -89.36%
1999 0.00%
Preço das ações de empresas similares ou concorrentes
Empresa Preço da ação Variação 1a% País
$171.67 -
DE
$164.46 25.10%
DE
$37.82 21.13%
JP
$222.79 32.01%
CH
$21.08 12.12%
IN